Cardiomyopathy

September 25, 2019

Published by admin_auro at September 25, 2019

Categories

Polypill for Cardioprotection: Polypill-HAAE/HAAV-based therapy for Cardiac repair and myocardial infarction: A four-component Polypill-HAAE/HAAV consisting of Hydrochlorothiazide (12·5 mg), Aspirin (81 mg), Atorvastatin (20 mg), and Enalapril (5 mg) or Valsartan (40 mg) increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 25/September/2019, 8.45 pm

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]

May 10, 2019

Published by admin_auro at May 10, 2019

Categories

Vasoactive Intestinal Peptide (PHM27/VIP)-based therapy protects against Cardiomyopathy: Vasoactive Intestinal Peptide (PHM27/VIP), a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 10/May/2019, 7.01 am

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]

May 7, 2019

Published by admin_auro at May 7, 2019

Categories

Mechanistic insights into how Canagliflozin protects against cardiomyopathy: Canagliflozin(Brand name: Invokana, Sulisent, Prominad), a sodium-glucose cotransporter-2 inhibitor used in the treatment of TIIDM, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 7/May/2019, 6.17 am

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]

May 3, 2019

Published by admin_auro at May 3, 2019

Categories

PIM-1-based therapy protects against Cardiomyopathy: PIM-1 (Proto-Oncogene, Serine/Threonine Kinase) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 3/May/2019, 11.40 pm

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]